Analysts think ADAP stock price could increase by 493%
Apr 06, 2025, 11:25 AM
14.60%
What does ADAP do
Adaptimmune Therapeutics Plc, a commercial-stage cell therapy company based in Abingdon, Oxfordshire, focuses on novel T-cell therapies for cancer, including afamitresgene autoleucel and Lete-cel. The company employs 449 people and went public on May 6, 2015.
11 analysts think ADAP stock price will increase by 492.56%. The current median analyst target is $1.53 compared to a current stock price of $0.26. The lowest analysts target is $1.01 and the highest analyst target is $3.68.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.